P/E ratio for Repligen (RGEN)

P/E ratio history for Repligen from 2001 to 2025

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Novavax NVAX	3.24	-99.94%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	19.8	-99.64%	🇺🇸 USA
Neurocrine Biosciences NBIX	35.8	-99.35%	🇺🇸 USA
General Electric GE	38.6	-99.30%	🇺🇸 USA
Thermo Fisher Scientific TMO	33.2	-99.40%	🇺🇸 USA
Bristol-Myers Squibb BMY	17.5	-99.68%	🇺🇸 USA
Pfizer PFE	14.9	-99.73%	🇺🇸 USA
Bio-Techne TECH	127	-97.70%	🇺🇸 USA
Sangamo Therapeutics SGMO	-1.20	-100.02%	🇺🇸 USA
Charles River Laboratories CRL	-119	-102.15%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.